JP2008195727A - Medicinal preparation - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a chewable tablet taken through chewing, which has high safety, excellent pharmaceutical safety, a bad breath alleviation effect and a saliva secretion stimulation effect. <P>SOLUTION: The chewable tablet taken through chewing contains a tea powder or a tea extract. The tea powder or the tea extract is a powder, an extract or an essence obtained through various processes from arbitrary portions including leaves, stems and buds of various teas such as green tea, powdered green tea, oolong tea, and black tea, for example, a green tea powder, powdered green tea (fine powder), an oolong tea extract and a black tea extract. <P>COPYRIGHT: (C)2008,JPO&INPIT

Description

The present invention relates to a pharmaceutical preparation characterized by blending tea powder or tea extract.

In the case of indigestion caused by inflammation of the gastrointestinal tract or overeating, it is a problem that unpleasant odor is generated by the undigested material staying in the gastrointestinal tract, resulting in discomfort. In conventional gastrointestinal drugs, efforts have been made to focus on improving gastric mucosal repair and digestion promoting effects. As a result, the gastric mucosal inflammation was repaired, the staying material was sent out, and as digestion progressed, it was only possible to eliminate the odor over time by a passive method based on the elimination of the cause of odor generation. Therefore, the conventional method using a gastrointestinal drug has not been effective for malodor caused by gastrointestinal disorders or bad breath caused by gastrointestinal function deterioration due to stress. On the other hand, medicines for gastrointestinal diseases have been improved by adding sweeteners, refreshing agents, and fragrances to reduce discomfort such as bitterness and smell when taken by patients. Was not considered at all.

An object of the present invention is to provide a pharmaceutical preparation that is excellent in the effect of reducing bad breath and has high safety and excellent pharmaceutical stability.

As a result of intensive studies to solve the above problems, the present inventors have formulated a tea powder or a tea extract into a pharmaceutical preparation, thereby providing a safe preparation excellent in preparation stability and excellent in bad breath prevention effect. It was found that can be obtained. It has been known that tea powder and tea extract have a bad breath suppression effect, but it has been known that when blended with a drug having an effect on gastrointestinal diseases, a sufficient bad breath suppression effect is exhibited. It is not done. The strength of the halitosis suppression effect is related to the dosage form and the formulation technology as well as the selection of the halitosis suppressor. It is more preferable to blend tea powder or tea extract as a solid preparation.

In addition, digestive agents, mucosal repair agents, antacids, and healthy gastric agents that are commonly used for gastrointestinal diseases have weak halitosis suppression activity, and these halitosis suppression activities can be combined with tea powder or tea extract. It was found to be enhanced. Further surprisingly, it has been found that blending tea powder or tea extract into a solid formulation improves formulation properties and enhances the stability of digestives and mucosal repair agents and the like. Digestives and mucosal repairing agents are components that are likely to cause problems such as a decrease in titer during formulation processing and stability after formulation. In particular, preparations formulated with antacids are more problematic in terms of overall formulation development, as stability is more likely to decline, but formulations containing tea powder or tea extract increase the stability of digestives and mucosal repair agents. It was found.

Accordingly, the present invention provides the following.
(1) a pharmaceutical preparation containing tea powder,
(2) a pharmaceutical preparation containing a pharmaceutically acceptable active ingredient and tea powder or tea extract,
(3) The pharmaceutical preparation according to item (1) or (2), wherein the pharmaceutical preparation is a solid preparation,
(4) The pharmaceutical formulation according to item (2) to (3), wherein the pharmaceutically acceptable active ingredient is an active ingredient for gastrointestinal diseases,
(5) The pharmaceutical preparation according to items (2) to (4), wherein the active ingredient for gastrointestinal disease is selected from the group consisting of an antacid, a mucosal repair agent, a gastric agent, an intestinal adjuster and a digestive agent.

The tea powder or tea extract used in the present invention refers to powders, extracts, extracts obtained from various parts such as green tea, matcha tea, oolong tea, black tea, etc. Examples thereof include green tea powder, green tea (fine powder), oolong tea extract, black tea extract and the like. These can be commercially available or can be prepared by ordinary methods. Green tea powder or green tea is preferred. The daily dose can be 0.01 mg to 300 mg, and can be appropriately increased or decreased depending on the dosage form, unit dose and the like.

The pharmaceutical preparation of the present invention suppresses or eliminates gastrointestinal disorders and associated bad breath by combining active ingredients such as antacids, mucosal repair agents, intestinal preparations, gastric agents, digestive agents and the like with tea powder or tea extract. be able to. The active ingredient used in the present invention includes, for example, dry aluminum hydroxide gel, magnesium aluminate silicate, magnesium silicate, synthetic aluminum silicate, synthetic hydrotalcite, sodium bicarbonate, magnesium carbonate, magnesium hydroxide, water Examples include antacids such as alumina magnesium oxide, cimetidine, ranitidine, and famotidine. In addition, sodium azulene sulfonate, aldioxa, glycyrrhizic acid and its salts, licorice extract, mucosal repair agents such as L-glutamine, copper chlorophyllin potassium, histidine hydrochloride, growth-grown fungi components and intestinals such as genokosho, katsumeishi, ubai, ogon , Gastric agents such as buckwheat, keihi, assembly, daiou and carrot, starch digestive enzymes, protein digestive enzymes, lipolytic enzymes, fibrin digestive enzymes, ursodeoxycholic acid, bile powder, bile extract and other digestives . In addition, an active ingredient such as an analgesic and antispasmodic agent such as scopolamine hydrobromide, methyl scopolamine bromide and papaverine hydrochloride, and an antidiarrheal agent such as berberine chloride, guaiacol, tannic acid, and precipitated calcium carbonate can also be blended. The compounding amount of these active ingredients is appropriately blended at a commonly used dose. The pharmaceutical preparation of the present invention has various dosage forms that can be administered orally, that is, solid preparations such as tablets, chewing agents, pills, powders, fine granules, granules, capsules, aqueous solutions, oil solutions, suspensions. Although it can be prepared and used for liquid preparations such as suspending agents, emulsions, syrups, etc., solid preparations are a preferred dosage form because of the effect of tea powder. Each of the above preparations is prepared by a conventional method, but if necessary, it is prepared using various additives.

Examples of additives used include excipients such as lactose, sucrose, corn starch, crystalline cellulose, mannitol, calcium carbonate, binders such as hydroxypropylmethylcellulose and hydroxypropylcellulose, talc, magnesium stearate, stear Lubricants such as calcium phosphate, disintegrants such as carboxymethylcellulose and low-substituted hydroxypropylcellulose, essential oil components such as l-menthol, peppermint oil and lemon oil, fragrances such as mint oil, and chlorophyll. The addition of chlorophyll increases the bad breath suppression effect, and the addition of an essential oil component is preferable because it increases the healthy stomach effect. In addition to these, additives commonly used in the production of solid preparations and liquid preparations such as solubilizers, stabilizers, emulsifiers, diluents, preservatives, sweeteners, and corrigents can be used. Specific examples of the pharmaceutical preparation of the present invention are described below, but the present invention is not limited thereto.

単位：（ｍｇ） Formulations comprising the components of Table 1 and Table 2 below were prepared.
Example 1-5

Unit: (mg)

単位：(ｍｇ)
以下に製造方法を示す。 Reference Example 1-6

Unit: (mg)
A manufacturing method is shown below.

Example 1
Xylitol, mannitol, hydroxypropyl cellulose, crystalline cellulose, magnesium carbonate, precipitated calcium carbonate, and synthetic hydrotalcite are mixed and granulated, dried and crushed by a conventional method to obtain a powder. Add green tea powder to the powder and mix. Further, an appropriate amount of magnesium stearate is added and mixed to obtain a mixed powder for tableting. Chewable tablets and tablets were obtained. Thereafter, the mixed powder for tableting was tableted to obtain chewable tablets (diameter 18 mm, hole diameter 6 mm) or tablets. In order to compare the effects, a chewable preparation or tablet obtained by removing green tea powder from the formulation of Example 1 as Reference Example 1 was obtained in the same manner as in Example 1. Tablets or chewable preparations having the component contents shown in Tables 1 and 2 per tablet were obtained.

Example 2
Xylitol, mannitol, hydroxypropyl cellulose, and crystalline cellulose are mixed and granulated, dried, and crushed by a conventional method to obtain a powder. Add green tea powder, biodiastase, lipase, and prozyme to the resulting powder and mix. Further, an appropriate amount of magnesium stearate is added and mixed to obtain a mixed powder for tableting. Thereafter, the mixed powder for tableting was tableted to obtain chewable tablets (diameter 18 mm, hole diameter 6 mm) or tablets. In order to compare the effects, a chewable preparation or tablet obtained by removing green tea powder from the formulation of Example 2 as Reference Example 2 was obtained in the same manner as in Example 2. Tablets or chewable preparations having the component contents shown in Tables 1 and 2 per tablet were obtained.

Example 3
Xylitol, mannitol, hydroxypropyl cellulose, and crystalline cellulose are mixed and granulated, dried, and crushed by a conventional method to obtain a powder. Add green tea powder, aldioxa and L-glutamine to the powder and mix. Further, an appropriate amount of magnesium stearate is added and mixed to obtain a mixed powder for tableting. Thereafter, the mixed powder for tableting is tableted to obtain chewable tablets (diameter 18 mm, hole diameter 6 mm), or tablets. In order to compare the effects, a chewable preparation or tablet obtained by removing green tea powder from the formulation of Example 3 as Reference Example 3 was obtained in the same manner as in Example 3. Tablets or chewable preparations having the component contents shown in Tables 1 and 2 per tablet were obtained.

Example 4
Xylitol, mannitol, hydroxypropyl cellulose, and crystalline cellulose are mixed and granulated, dried, and crushed by a conventional method to obtain a powder. Add green tea powder, carrot powder and Keihi powder to the powder. Further, an appropriate amount of magnesium stearate is added and mixed to obtain a mixed powder for tableting. Thereafter, the mixed powder for tableting is tableted to obtain chewable tablets (diameter 18 mm, hole diameter 6 mm), or tablets. In order to compare the effect, a chewable preparation or tablet obtained by removing green tea powder from the formulation of Example 1 as Reference Example 4 was obtained in the same manner as in Example 1. In order to compare the effects, a chewable preparation or tablet obtained by removing green tea powder from the formulation of Example 4 as Reference Example 4 was obtained in the same manner as in Example 4. Tablets or chewable preparations having the component contents shown in Tables 1 and 2 per tablet were obtained.

Example 5
Xylitol, mannitol, hydroxypropyl cellulose, crystalline cellulose, magnesium carbonate, precipitated calcium carbonate, and synthetic hydrotalcite are granulated, dried and crushed by a conventional method to obtain a powder. Add green tea powder, biodiastase, lipase, prozyme, aldioxa and L-glutamine to the powdered powder and mix. Further, an appropriate amount of magnesium stearate is added and mixed to obtain a mixed powder for tableting. Thereafter, the mixed powder for tableting is tableted to obtain chewable tablets (diameter 18 mm, hole diameter 6 mm), or tablets. In order to compare the effect, a chewable preparation or tablet obtained by removing green tea powder from the formulation of Example 5 as Reference Example 5 was obtained in the same manner as in Example 5. Tablets or chewable preparations having the component contents shown in Tables 1 and 2 per tablet were obtained.

Test Example 1 Mixability Improvement In Example 1 and Reference Example 1, 525 g of xylitol, 220 g or 250 g of mannitol, 50 g of hydroxypropyl cellulose, 25 g of crystalline cellulose, 150 g of magnesium carbonate, 200 g of precipitated calcium carbonate, and 100 g of synthetic hydrotalcite were mixed. The powder is produced by granulation, drying, and crushing by a conventional method. The powder of Example 1 thus obtained and 30 g of green tea powder and 10 g of aldioxa, or the powder of Reference Example 1 and 10 g of aldioxa are charged into a V-type mixer (manufactured by Showa Kogyo Co., Ltd., V3) and mixed at a rotational speed of 14 rpm. After mixing, after 5, 10, 15, 30, 45, 60 minutes from the start of mixing, 150 to 200 mg of mixed powder samples are collected from five different locations in the mixer, The amount of allantoin (component in aldioxa) is quantified by liquid high performance chromatography. A variation value (standard deviation of 5 samples / average value of 5 samples) of samples collected at 5 different places was calculated from the quantitative value of allantoin, and the degree of mixing was evaluated. Table 3 shows the results. Good uniformity was obtained from the beginning of mixing by blending tea powder. When preparing mixed granules for tableting, it is difficult to mix fine powder, which causes uneven accumulation. It is difficult to obtain a uniform mixture by mixing for a short time only by mixing the granulated product and aldioxa, but when green tea powder is added and mixed at the same time, the component uniformity of the mixed powder is improved.

Table 3 Transition of mixing degree

Test Example 2 Improving tableting characteristics Using a tableting machine (HT-E5-S, manufactured by Hata Seisakusho), the mixed granules were rotated at a speed of 15-20 rpm, a tableting pressure of 4-5 t / kg, and both R surfaces were perforated. A ring tablet, a chewable agent having a size of 18 mm in diameter and a hole diameter of 6 mm was continuously tableted for 8 hours. When the appearances of the chewable preparations of Examples 1 to 5 and Reference Examples 1 to 5 were visually observed, in Reference Example 1, tableting troubles such as binding, capping and sticking were observed from around 30 minutes of tableting time. In Example 1, no tableting failure was observed. Moreover, the mixed powders of Examples 1 to 5 were superior in binding strength to Reference Examples 1 to 5 and exhibited high tablet hardness.

Test Example 3 Improvement of disintegration of tablets A disintegration test was performed according to the Japanese Pharmacopoeia 12th edition. In Examples 1 to 5, all the tablets disintegrated within 15 to 20 minutes as specified. On the other hand, in Reference Examples 1-5, the dispersion | variation in decay | disintegration time was large and was 25-40 minutes, and it may exceed 30 minutes which is a regulation value.

Test Example 4 Deodorizing Effect of Malodorous Substance 1 ml of methyl mercaptan and 50 ml of water were placed in a 200 ml suction bottle as a malodorous solution and stirred for 1 minute. The gas in the suction bottle of methyl mercaptan is introduced into the detector tube, and the concentration of methyl mercaptan is measured and used as a control value. In another suction bottle, 1 ml of methyl mercaptan and the chewable tablets of Examples 1 to 5 and Reference Examples 1 to 5 were pulverized, 400 mg of the powdered sample and 50 ml of water were added and stirred for 1 minute, and the gas in the suction bottle To the detector tube and measure the methyl mercaptan concentration. Furthermore, in order to confirm the deodorizing effect of green tea powder, except for magnesium carbonate, precipitated calcium carbonate, and synthetic hydrotalcite from the formulation of Example 1, Reference Example 6 produced in the same manner was obtained. The mercaptan concentration was measured. (Difference between the control value and the measured value of the specimen) / Deodorization rate (%) as the deodorization rate (%), and the deodorization rate of green tea powder was evaluated by comparing the deodorization rate. The results are shown in Table 4. .
Table 4 Deodorizing effect

Test Example 5 Stability Improvement The ring tablet chewable agent of Example 5 and Reference Example 5 was hermetically packaged with an aluminum laminate film in units of 30 tablets, and stored in a thermostatic device at 40 degrees. The packaged product was taken out over time, and the tablets were crushed for analysis. The effect of green tea powder on the stability of blended aldioxa and digestive enzymes was evaluated. As an evaluation of the stability of the digestive enzymes biodiastase, lipase, and prozyme aldiaxa, saccharification, protein digestion and fat digestion were quantified, and allantoin content was quantified as an evaluation of the stability of aldiaxa. The residual rate (residual rate (%) = quantitative value / initial value) was determined from the quantitative value and the initial value after one month, two months, three months, and six months of the storage period. The preparation of the present invention was shown to have high digestive enzyme activity and allantoin stability. The results are shown in Table 5.

注：表中の（−）はデータがないことを示す。 Table 5 Stability test

Note: (-) in the table indicates no data.

Test Example 6 Salivary secretion promoting action The effect brought about by chewing at the time of taking was tested. The saliva accumulated in the mouth for 5 minutes with the mouth left still was discharged, and the saliva weight was measured to obtain a normal secretion amount. Subsequently, the chewable tablets of Examples 1, 2, and 5 were chewed in the mouth for 30 seconds, and after being held in the mouth for 30 seconds, all were exhaled, and the weight of saliva secreted when taking orally chewing was measured. Moreover, the saliva weight discharged in a stationary state was measured every 5 minutes from the first discharge, and this was taken as the trend of the saliva weight secreted after taking. The test was conducted by five volunteers. In addition, a placebo tableted with only lactose was used. Table 6 shows the ratio of (saliva secretion after administration) to (saliva secretion during normal use). All examples promoted salivation and were particularly remarkable in Example 5, which is a combined formulation. Since saliva has amylase activity, it is more preferable to increase the amount of saliva secretion because the digestive action is increased.
Table 6 (Time-varying saliva secretion / normal saliva secretion)

Test Example 7 Action on Antacid by Chewing The tablets of Example 5 were discharged together with saliva after chewing, and the action of saliva on the antacid was observed by the modified Fuchs method. Chew the tablet until it becomes fine, hold it in the mouth for 5 minutes, and then discharge it. Then, twice every 5 minutes, dilute the saliva accumulated in the mouth with water to make 45 ml. It was added at a rate of 2 ml / min. The pH curve immediately after the addition of 5 ml of 1N hydrochloric acid test solution was observed. As a control, one tablet of Example 5 was ground and tested in the same manner. In the case of chewing and mixing with saliva, a marked improvement in antacid action was observed 10 minutes after the start of measurement.

Test Example 8 Improvement of lipophilicity by chewing After the tablet of Example 5 was chewed and held in the mouth for 5 minutes, all of it was discharged together with saliva. 10 ml of the discharged chewing mixture and 5 ml of olive oil are placed in a 20 ml capacity centrifuge tube with a stopper and shaken for 10 minutes. After standing, the content liquid quickly separated into an aqueous layer and an emulsion layer. After 10 minutes of standing, only the emulsion layer was separated, and a 1: 1 mixed powder of hydrophilic colorant Blue No. 1 and lipophilic colorant Sudan 3 was added and shaken. As a control, the same operation was performed using purified water instead of the chewing mixture. In the case of the chewing mixture, the emulsion was blue and was of O / W type, whereas the control emulsion was mixed with blue and red. It was shown that by chewing the tablet of Example 9, it was emulsified in a short time, the lipophilicity of the chewing mixture was increased, and the effect of promoting fat digestion in the digestive tract was shown.

Test Example 9 Bad breath removal effect Breath breath removal effect when taken by 6 volunteer subjects according to the following procedure, breath was sampled and collected using an odor sensor (parent Cosmo Electric, XP-329) The odor concentration was measured. (1) After mouth-washing with 50 ml of water, exhaled air is discharged into a 2 L plastic bag. (2) After chewing the chewable tablet of Example 5 for 1 minute, spit all out and rinse with 50 ml of water. Immediately after that, the exhaled air is discharged into a 2L vinyl bag. (3) After mouth-rinsing with 50 ml of water, exhaled air is discharged into a 2 L vinyl bag. (4) After chewing 2 g of raw grated garlic for 1 minute, spit out everything and rinse with 50 ml of water. Immediately after that, the exhaled air is discharged into a 2 L capacity vinyl bag. (5) After mouthwashing with 50 ml of water, exhaled air is discharged into a 2 L capacity vinyl bag. (6) Chew 1 chewable tablet and 2 g of grated garlic at the same time for 1 minute, then spit out everything and rinse with 50 ml of water. Exhale immediately after mouthwash is discharged into a 2L plastic bag. From the measured values of the breath samples of (1) to (6), the residual odor rate was determined from the following equation.
Residual rate (%) = {(Odor concentration in exhaled breath after chewable and garlic chewing−Odor concentration in exhaled breath after chewable chewing) / Odor concentration in exhaled breath after chewing garlic} × 100 = [{((6) − (5))-((2)-(1))} / ((4)-(3))] x100
By taking the chewable tablet of Example 5, it was found that the residual rate of odor immediately after taking garlic was 31.6%, and about 70% of the odor was removed.

Claims (1)

Chewable tablets containing tea powder or tea extract for chewing and taking.